查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2018679

胃食道逆流症治療市場：2026年至2032年全球市場預測（依治療方法、劑型、給藥途徑、藥物類型、藥物核准情況、疾病嚴重程度、分銷管道及最終用戶分類）

Gastroesophageal Reflux Disease Therapeutics Market by Treatment Type, Dosage Form, Route Of Administration, Medicine Type, Drug Status, Disease Severity, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，胃食道逆流症 (GERD) 治療市場價值將達到 54.6 億美元，到 2026 年將成長至 57.4 億美元，到 2032 年將達到 78.8 億美元，複合年成長率為 5.36%。

主要市場統計數據
基準年 2025 54.6億美元
預計年份：2026年 57.4億美元
預測年份 2032 78.8億美元
複合年成長率 (%) 5.36%

對不斷發展的治療格局、臨床因素、患者需求以及影響胃食道逆流治療的策略重點進行簡明扼要而全面的介紹。

胃食道逆流症 (GERD) 在醫療保健領域佔據核心地位，這主要歸因於持續的症狀負擔、不斷發展的臨床路徑以及患者期望的改變。近年來，臨床實踐一直在努力平衡長期應用的抑酸療法與日益成長的對長期安全性、按需管理以及輔助機械或內視鏡干預的關注。因此，臨床、商業和監管領域的相關人員正在重新評估治療重點和投資決策。

變革性的變化正在透過藥物創新、手術干預以及以患者為中心的數位化解決方案和診斷技術重新定義胃食道逆流 (GERD) 的治療路徑。

隨著創新與不斷發展的醫療服務模式以及患者對安全性和個人化治療日益成長的期望相融合，胃食道逆流（GERD）的治療格局正在經歷一場變革。在藥物治療方面，新型抑酸藥物和替代作用機制的出現，迫使臨床醫師重新思考長期治療策略。同時，特定市場證據的累積和監管核准的獲批，為傳統質子幫浦阻斷劑以外的更多臨床治療選擇提供了可能。此外，微創手術和器械輔助治療正從專科中心推廣到更廣泛的臨床應用，為尋求緩解難治性疾病和擺脫藥物依賴的患者提供了新的選擇。

基於證據的評估，分析 2025 年關稅變化將如何累積重塑 GERD 的供應鏈、籌資策略以及整個價值鏈的商業性決策。

貿易政策的發展，包括2025年實施的關稅調整，正在給整個藥品生產、分銷和採購流程帶來累積壓力。原料、活性藥物成分、醫療設備組件和包裝材料的關稅推高了投入成本，給利潤率本就微薄的學名藥藥和品牌藥生產商帶來了挑戰。為了應對這些挑戰，許多企業正在加快供應商多元化，增加對區域製造地的依賴，並實施長期合約保障措施，以確保關鍵投入材料的穩定供應。

以細分市場主導的洞察，將治療方法、分銷管道、給藥途徑/劑型以及患者的最終用戶環境與策略重點聯繫起來。

市場細分為將治療方案的研發、商業策略和分銷策略與患者需求和臨床實踐相匹配提供了一個框架。基於治療類型，市場研究涵蓋以下幾個領域：制酸劑、H2受體拮抗劑、促動力藥和質子幫浦阻斷劑。 H2受體拮抗劑的品牌藥和非專利分別進行了進一步分析。質子幫浦阻斷劑的品牌藥和非專利藥也分別進行了進一步分析。這種在治療層面進行的詳細分析突顯了速效非處方藥、按需處方藥和持續抑制療法並存的現狀，並明確了創新和製劑改進能夠帶來臨床優勢的領域。

美洲、歐洲、中東和非洲以及亞太地區在臨床實踐、監管和供應鏈方面的區域差異，造成了不同的策略挑戰。

區域趨勢對臨床實踐模式、監管時間表和供應鏈結構有顯著影響，從而在全球範圍內造成了不同的策略挑戰。在美洲，臨床實踐的特點是廣泛採用成熟的抑酸療法、門診治療日益增多，以及競爭激烈的市場環境，這既促進了品牌差異化，也提高了學名藥的療效。醫療保健系統和保險公司通常優先考慮實際療效和處方集匹配度，從而影響醫療服務提供者的處方行為和生產商的准入策略。

決定胃食道逆流症治療商業性和臨床成功的製藥、醫療設備和製造相關人員的策略行動和競爭定位。

胃食道逆流症（GERD）治療領域的企業正採取一系列策略舉措，以避免競爭並提升臨床影響力。老牌製藥公司在管理已上市多年的抑酸產品生命週期的同時，也選擇性地投資於新型作用機制和製劑改進，以提升安全性、依從性和按需用藥的安全性。非專利生產商則持續最佳化成本結構，拓展經銷夥伴，以維持在零售和醫院通路的市場滲透率。同時，專業醫療設備製造商正致力於累積臨床證據，以擴大其內視鏡和植入式解決方案的應用。

為加強胃食道逆流症治療中的供應鏈、臨床差異化、支付方合作、數位化支持和監管合規性，向經營團隊提出切實可行的建議。

產業領導者應採取多管齊下的策略，將臨床創新與營運韌性和市場彈性結合。首先，他們應優先建立多元化且具韌性的供應鏈，具體措施包括：認證關鍵活性原料藥（API）和組件的替代供應商；投資區域製造夥伴關係；以及實施先進的庫存管理和需求預測能力，以降低關稅和物流波動風險。其次，他們應透過投資臨床計畫來推動治療差異化，這些計畫旨在評估聯合治療療法和輔助療法，以明確患者表現型，證明其在長期使用中的相對安全性，並減少對長期高劑量抑酸治療的依賴。

調查方法穩健的混合方法來檢驗見解和建議，結合專家訪談、文獻整合、供應鏈映射和情境分析。

本執行摘要的分析採用了混合研究途徑，以確保其深度、相關性和可操作性。關鍵的定性資料包括對臨床關鍵意見領袖、醫院藥劑師、專科診所經理和高級採購負責人的結構化訪談，以了解處方行為、醫療設備應用和供應鏈風險等方面的實際觀點。二手研究則整合了同儕審查文獻、最新臨床指南、監管申報文件和產品說明，以檢驗治療機制、近期核准以及診斷技術的進步。

簡潔扼要的結論重點強調了將塑造未來 GERD 治療策略的新機會、營運挑戰和綜合優先事項。

總而言之，胃食道逆流（GERD）治療生態系統呈現出穩定的臨床需求、意義深遠的創新以及日益複雜的運作的特徵。新藥類別和微創手術的出現拓展了治療選擇，而不斷發展的診斷技術和數位化工具則助力實現更精準、以患者為中心的醫療服務。同時，包括關稅趨勢和流通結構變化在內的商業性和供應鏈壓力，正迫使企業重新思考其在採購、製造地和銷售管道的運作方式。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：胃食道逆流症治療市場－依治療方法分類

  • 藥物治療
    • 質子幫浦阻斷劑（PPI）
    • H2受體拮抗劑
    • 制酸劑
    • 黏膜敷料
      • 硫糖鋁和包衣劑
      • 藻酸鹽/筏狀形成劑
  • 手術介入
  • 器械療法

第9章 依劑型分類的胃食道逆流治療市場

  • 膠囊
  • 液體
  • 懸浮液
  • 藥片

第10章：胃食道逆流症治療市場：依給藥途徑分類

  • 口服
  • 注射藥物

第11章：胃食道逆流症治療藥物市場－依藥物類型分類

  • 非處方藥
  • 處方藥

第12章：胃食道逆流症治療藥物市場－依藥物狀態分類

  • 品牌商品
  • 非專利的

第13章：依疾病嚴重程度分類的胃食道逆流治療市場

  • 溫和的
  • 緩和
  • 嚴重

第14章：胃食道逆流症治療市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第15章：胃食道逆流症治療市場：依最終用戶分類

  • 居家醫療
  • 醫院
  • 專科診所

第16章：胃食道逆流症治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第17章：胃食道逆流症治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第18章：胃食道逆流症治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第19章：美國胃食道逆流症治療市場

第20章：中國胃食道逆流症治療市場

第21章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AstraZeneca plc
  • Aurobindo Pharma Limited
  • Bayer AG
  • Cadila Pharmaceuticals Ltd.
  • Camber Pharmaceuticals, Inc.
  • Daewoong Pharmaceutical Co., Ltd.
  • Dr. Reddy's Laboratories Limited
  • Eisai Co., Ltd.
  • Elite Wealth Ltd.
  • Haleon plc
  • HK inno.N Co., Ltd.
  • Ironwood Pharmaceuticals, Inc.
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • Onconic Therapeutics Inc.
  • Pfizer Inc.
  • Phathom Pharmaceuticals, Inc.
  • RaQualia Pharma Inc.
  • Reckitt Benckiser Group plc
  • Sandoz Group AG
  • Sanofi SA
  • Sebela Pharmaceuticals Inc.
  • Sun Pharmaceutical Industries Limited
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • The Procter & Gamble Company
  • Viatris Inc.
Product Code: MRR-AD36CD897D13

The Gastroesophageal Reflux Disease Therapeutics Market was valued at USD 5.46 billion in 2025 and is projected to grow to USD 5.74 billion in 2026, with a CAGR of 5.36%, reaching USD 7.88 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.46 billion
Estimated Year [2026] USD 5.74 billion
Forecast Year [2032] USD 7.88 billion
CAGR (%) 5.36%

A concise yet comprehensive introduction to the evolving therapeutic landscape, clinical drivers, patient needs, and strategic priorities shaping GERD treatments

Gastroesophageal reflux disease occupies a central position in digestive healthcare, driven by persistent symptom burden, evolving clinical pathways, and shifting patient expectations. In recent years clinical practice has balanced long-established acid suppression approaches with growing attention to long-term safety, on-demand management, and complementary mechanical or endoscopic interventions. As a result, stakeholders across clinical, commercial, and regulatory spheres are reassessing therapeutic priorities and investment decisions.

Consequently, clinicians are increasingly focused on differentiating patient phenotypes, optimizing diagnostic algorithms, and tailoring treatments to symptom patterns and treatment response. Pivotal changes in therapeutic options, the rise of novel acid suppression classes, and broader access to minimally invasive procedures have widened the spectrum of care without eliminating the central role of evidence-based pharmacotherapy. At the same time, payer scrutiny, generics competition, and outpatient management trends are reshaping prescribing and distribution behaviors.

Taken together, these dynamics create both complexity and opportunity for product developers, manufacturers, and health systems. Therefore, strategic clarity requires an integrated view that connects clinical trends, supply chain realities, and patient-centered delivery models to inform pragmatic decisions that enhance outcomes while maintaining commercial viability.

Transformative shifts redefining GERD care pathways through pharmacologic innovation, procedural interventions, and patient-centric digital solutions and diagnostics

The GERD therapeutic landscape is undergoing transformative shifts as innovation converges with changing care delivery models and heightened expectations for safety and personalization. On the pharmacologic front, new classes of acid suppression and alternative mechanisms are prompting clinicians to reconsider long-term management strategies, while growing evidence and regulatory approvals in select markets have introduced clinically meaningful options beyond traditional proton pump inhibitors. In parallel, minimally invasive and device-mediated procedures have moved from niche referral centers toward broader clinical adoption, offering alternatives for refractory disease and patients seeking reduced pharmacologic dependence.

Meanwhile, diagnostics are becoming more nuanced, with enhanced ambulatory and impedance monitoring facilitating phenotype-driven therapy. Digital tools that support adherence, symptom tracking, and telehealth consultations are reshaping continuity of care and enabling more responsive titration of therapies. Moreover, the interplay between generics and branded innovation is driving strategic portfolio adjustments, partnership models, and go-to-market approaches. As a result, manufacturers and providers must navigate a multidimensional environment where clinical differentiation, cost-effectiveness, and patient experience determine uptake and sustained use.

An evidence-based appraisal of how 2025 tariff shifts cumulatively reshape GERD supply chains, procurement strategies, and commercial decision-making across the value chain

Trade policy developments, including tariff adjustments implemented during 2025, introduce cumulative pressures that reverberate across pharmaceutical manufacturing, distribution, and procurement. Tariffs on raw materials, active pharmaceutical ingredients, device components, and packaging can elevate input costs, thereby challenging manufacturers that operate on narrow margins in generic and branded segments alike. In response, many organizations accelerate supplier diversification, increase reliance on regional manufacturing hubs, and pursue longer-term contractual protections to stabilize access to critical inputs.

Consequently, procurement teams and commercial leaders are reassessing sourcing footprints to reduce exposure to import duties and transportation volatility. For specialty devices and contract manufacturing, tariff-induced cost increases tend to favor near-shore or onshore production where regulatory and labor conditions permit, though capital and technical constraints can limit near-term shifts. From a distribution perspective, hospital formularies and outpatient providers may face heightened negotiation pressure with suppliers as cost escalation intersects with payer expectations for affordability and value-based contracting.

Taken together, these dynamics highlight the importance of proactive supply chain risk assessment, scenario planning, and strategic supplier partnerships to mitigate tariff impacts. Firms that invest in supply chain transparency, adaptive sourcing, and inventory optimization can preserve clinical continuity while protecting commercial margins in an increasingly complex trade environment.

Segment-driven insights that connect treatment modalities, distribution channels, routes and forms of administration, and patient end-user contexts to strategic priorities

Segmentation provides the framework to align therapeutic development, commercial tactics, and distribution strategies with patient needs and clinical settings. Based on Treatment Type, market is studied across Antacids, H2 Receptor Antagonists, Prokinetics, and Proton Pump Inhibitors. The H2 Receptor Antagonists is further studied across Branded and Generic. The Proton Pump Inhibitors is further studied across Branded and Generic. This treatment-level granularity underscores the coexistence of rapid-onset OTC options, on-demand prescriptions, and durable suppression therapies, and it clarifies where innovation or reformulation can create clinical advantage.

Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies. This distribution perspective reveals differential access patterns for acute inpatient care versus chronic outpatient management, and it highlights the growing importance of e-commerce for therapy continuity and adherence. Based on Route Of Administration, market is studied across Intravenous and Oral. Intravenous formulations remain critical for perioperative and hospitalized patients, while oral therapies dominate ambulatory care and home treatment strategies. Based on Dosage Form, market is studied across Capsule, Liquid, Suspension, and Tablet. Dosage form diversity supports age- and comorbidity-appropriate prescribing and adherence initiatives, particularly for pediatric, geriatric, and dysphagia-prone populations. Based on Patient End User, market is studied across Home Care Settings, Hospitals, and Specialty Clinics. Understanding end-user dynamics guides commercial outreach, patient support programs, and clinical education to ensure therapy alignment with care settings and patient expectations.

Therefore, segmentation-led insight enables targeted R&D prioritization, precise channel strategies, and tailored clinical support that collectively improve uptake and patient outcomes.

Regional clinical, regulatory, and supply chain nuances across the Americas, Europe Middle East & Africa, and Asia-Pacific that define differentiated strategic imperatives

Regional dynamics materially influence clinical practice patterns, regulatory timelines, and supply chain architectures, creating differentiated strategic imperatives across the globe. In the Americas, clinical practice is characterized by widespread adoption of established acid-suppression therapies, growing outpatient management, and a competitive landscape that incentivizes both branded differentiation and generic efficiency. Health systems and payers often emphasize real-world outcomes and formulary alignment, which in turn shapes provider prescribing and manufacturer access strategies.

In Europe, Middle East & Africa, heterogeneous regulatory frameworks and variable healthcare infrastructures demand regionally adapted approaches. Some countries prioritize value assessments and cost-effectiveness, while others emphasize access and primary care management. Consequently, manufacturers must align dossier development, pricing strategies, and local market partnerships to navigate reimbursement pathways and cultivate specialist referral networks. In Asia-Pacific, rapid urbanization, changing dietary patterns, and shifting diagnostic awareness have influenced prevalence and treatment demand. Additionally, certain markets in the region have been early adopters of new acid-suppression technologies, and manufacturing capacity in Asia-Pacific remains a strategic asset for both regional supply and global export.

Across these regions, regulatory trends, clinical guideline updates, and tariff considerations interact to influence launch sequencing, procurement planning, and local commercial models. Recognizing these regional nuances enables more precise investment prioritization and executional planning.

Strategic behaviors and competitive positioning among pharmaceutical, device, and manufacturing stakeholders that determine commercial and clinical success in GERD therapeutics

Companies operating in the GERD therapeutics space are pursuing a spectrum of strategic moves to preserve competitiveness and capture clinical relevance. Established pharmaceutical firms are balancing lifecycle management for long-standing acid-suppression products with selective investments in novel mechanisms and reformulations that address safety, adherence, and on-demand use. Generic manufacturers continue to optimize cost structures and expand distribution partnerships to maintain penetration across retail and hospital channels, while specialized device companies focus on clinical evidence generation to broaden adoption of endoscopic and implantable solutions.

Additionally, contract development and manufacturing organizations play an increasingly pivotal role as companies seek flexible, regulatory-compliant production capacity that supports both oral and intravenous forms across multiple dosage formats. Strategic collaborations between pharmaceutical developers and digital health vendors are emerging to create patient support ecosystems that improve adherence and capture real-world data. In parallel, commercial teams are refining payer engagement strategies to emphasize value-based outcomes and to secure formulary positioning amid heightened cost scrutiny. Collectively, these organizational approaches reflect an ecosystem where clinical differentiation, evidence generation, and operational resilience determine long-term success.

Actionable recommendations for leaders to strengthen supply chains, clinical differentiation, payer engagement, digital support, and regulatory alignment in GERD care

Industry leaders should adopt a multi-pronged strategy that aligns clinical innovation with operational resilience and market-facing agility. First, prioritize diversified and resilient supply chains by qualifying alternate suppliers for key APIs and components, investing in regional manufacturing partnerships, and implementing advanced inventory and demand-sensing capabilities to mitigate tariff and logistics volatility. Second, advance therapeutic differentiation by investing in clinical programs that clarify patient phenotypes, demonstrate comparative safety for long-term use, and evaluate combination or adjunctive approaches that reduce dependence on chronic high-dose acid suppression.

Third, strengthen payer and provider engagement through real-world evidence programs, outcomes-based contracting pilots, and targeted educational initiatives aimed at specialty clinics and hospital formularies to communicate value propositions effectively. Fourth, accelerate digital and patient support offerings that enhance adherence, personalized dosing, and telehealth integration, thereby improving outcomes and reducing unnecessary escalation to invasive procedures. Fifth, tailor commercial models across distribution channels by optimizing online pharmacy partnerships for chronic therapy continuity while maintaining hospital and retail access for acute and inpatient settings. Finally, ensure regulatory alignment by proactively engaging authorities on labeling, safety monitoring, and post-market evidence generation to facilitate access and maintain clinician confidence.

By executing these recommendations concurrently, organizations can protect margins, enhance patient outcomes, and sustain competitive advantage in a rapidly evolving therapeutic landscape.

A robust mixed-methods research methodology combining expert interviews, literature synthesis, supply chain mapping, and scenario analysis to validate insights and recommendations

The analysis underpinning this executive summary integrates a mixed-methods research approach to ensure depth, validity, and practical relevance. Primary qualitative inputs include structured interviews with clinical key opinion leaders, hospital pharmacists, specialty clinic directors, and senior procurement professionals to capture frontline perspectives on prescribing behavior, device adoption, and supply chain risks. Secondary research synthesized peer-reviewed literature, clinical guideline updates, public regulatory filings, and product monographs to validate therapeutic mechanisms, recent approvals, and diagnostic advancements.

Operational and commercial dimensions were examined through supply chain mapping exercises, review of import/export exposure, and scenario-based tariff impact modeling to identify stress points and mitigation options. Data triangulation methods were applied to reconcile divergent inputs and to ensure consistent interpretation across clinical, regulatory, and commercial domains. Finally, stakeholder validation workshops were conducted to refine conclusions, stress-test recommendations, and align insights with pragmatic implementation pathways for manufacturers, providers, and distributors.

This methodological blend of qualitative and quantitative techniques delivers a holistic perspective designed to support strategic decision-making without relying solely on single-source data points.

A concise conclusion highlighting emerging opportunities, operational challenges, and the integrated priorities that will shape future GERD therapeutic strategies

In summary, the GERD therapeutics ecosystem is characterized by steady clinical demand, meaningful innovation, and mounting operational complexity. Novel pharmacologic classes and minimally invasive procedures expand treatment choices, while evolving diagnostics and digital tools enable more precise, patient-centered care. At the same time, commercial and supply chain pressures, including tariff dynamics and distribution shifts, require companies to rethink sourcing, manufacturing footprints, and channel engagement.

Looking ahead, sustained success will depend on the ability to integrate clinical differentiation with resilient operations and evidence-led payer discussions. Organizations that invest in targeted clinical programs, diversify supply chains, and deploy digital adherence solutions will be better positioned to respond to regional nuances and evolving clinical guidelines. As stakeholders navigate this landscape, continuous alignment between R&D priorities, commercial execution, and patient support will be essential to deliver improved outcomes and long-term value.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Gastroesophageal Reflux Disease Therapeutics Market, by Treatment Type

  • 8.1. Pharmacologic Therapies
    • 8.1.1. Proton Pump Inhibitors (PPIs)
    • 8.1.2. H2 Receptor Antagonists
    • 8.1.3. Antacid
    • 8.1.4. Mucosal Coating Agent
      • 8.1.4.1. Sucralfate & Coating Agents
      • 8.1.4.2. Alginates/Raft Formers
  • 8.2. Surgical Interventions
  • 8.3. Device-Based Therapies

9. Gastroesophageal Reflux Disease Therapeutics Market, by Dosage Form

  • 9.1. Capsule
  • 9.2. Liquid
  • 9.3. Suspension
  • 9.4. Tablet

10. Gastroesophageal Reflux Disease Therapeutics Market, by Route Of Administration

  • 10.1. Oral
  • 10.2. Injectable

11. Gastroesophageal Reflux Disease Therapeutics Market, by Medicine Type

  • 11.1. Over-The-Counter
  • 11.2. Prescription

12. Gastroesophageal Reflux Disease Therapeutics Market, by Drug Status

  • 12.1. Branded
  • 12.2. Generic

13. Gastroesophageal Reflux Disease Therapeutics Market, by Disease Severity

  • 13.1. Mild
  • 13.2. Moderate
  • 13.3. Severe

14. Gastroesophageal Reflux Disease Therapeutics Market, by Distribution Channel

  • 14.1. Hospital Pharmacies
  • 14.2. Online Pharmacies
  • 14.3. Retail Pharmacies

15. Gastroesophageal Reflux Disease Therapeutics Market, by End User

  • 15.1. Home Care Settings
  • 15.2. Hospitals
  • 15.3. Specialty Clinics

16. Gastroesophageal Reflux Disease Therapeutics Market, by Region

  • 16.1. Americas
    • 16.1.1. North America
    • 16.1.2. Latin America
  • 16.2. Europe, Middle East & Africa
    • 16.2.1. Europe
    • 16.2.2. Middle East
    • 16.2.3. Africa
  • 16.3. Asia-Pacific

17. Gastroesophageal Reflux Disease Therapeutics Market, by Group

  • 17.1. ASEAN
  • 17.2. GCC
  • 17.3. European Union
  • 17.4. BRICS
  • 17.5. G7
  • 17.6. NATO

18. Gastroesophageal Reflux Disease Therapeutics Market, by Country

  • 18.1. United States
  • 18.2. Canada
  • 18.3. Mexico
  • 18.4. Brazil
  • 18.5. United Kingdom
  • 18.6. Germany
  • 18.7. France
  • 18.8. Russia
  • 18.9. Italy
  • 18.10. Spain
  • 18.11. China
  • 18.12. India
  • 18.13. Japan
  • 18.14. Australia
  • 18.15. South Korea

19. United States Gastroesophageal Reflux Disease Therapeutics Market

20. China Gastroesophageal Reflux Disease Therapeutics Market

21. Competitive Landscape

  • 21.1. Market Concentration Analysis, 2025
    • 21.1.1. Concentration Ratio (CR)
    • 21.1.2. Herfindahl Hirschman Index (HHI)
  • 21.2. Recent Developments & Impact Analysis, 2025
  • 21.3. Product Portfolio Analysis, 2025
  • 21.4. Benchmarking Analysis, 2025
  • 21.5. AstraZeneca plc
  • 21.6. Aurobindo Pharma Limited
  • 21.7. Bayer AG
  • 21.8. Cadila Pharmaceuticals Ltd.
  • 21.9. Camber Pharmaceuticals, Inc.
  • 21.10. Daewoong Pharmaceutical Co., Ltd.
  • 21.11. Dr. Reddy's Laboratories Limited
  • 21.12. Eisai Co., Ltd.
  • 21.13. Elite Wealth Ltd.
  • 21.14. Haleon plc
  • 21.15. HK inno.N Co., Ltd.
  • 21.16. Ironwood Pharmaceuticals, Inc.
  • 21.17. Johnson & Johnson Services, Inc.
  • 21.18. Lupin Limited
  • 21.19. Onconic Therapeutics Inc.
  • 21.20. Pfizer Inc.
  • 21.21. Phathom Pharmaceuticals, Inc.
  • 21.22. RaQualia Pharma Inc.
  • 21.23. Reckitt Benckiser Group plc
  • 21.24. Sandoz Group AG
  • 21.25. Sanofi S.A.
  • 21.26. Sebela Pharmaceuticals Inc.
  • 21.27. Sun Pharmaceutical Industries Limited
  • 21.28. Takeda Pharmaceutical Company Limited
  • 21.29. Teva Pharmaceutical Industries Ltd.
  • 21.30. The Procter & Gamble Company
  • 21.31. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MEDICINE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG STATUS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 15. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 16. CHINA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOLOGIC THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOLOGIC THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOLOGIC THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS (PPIS), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS (PPIS), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS (PPIS), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ANTACID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ANTACID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ANTACID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MUCOSAL COATING AGENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MUCOSAL COATING AGENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MUCOSAL COATING AGENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MUCOSAL COATING AGENT, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY SUCRALFATE & COATING AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY SUCRALFATE & COATING AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY SUCRALFATE & COATING AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ALGINATES/RAFT FORMERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ALGINATES/RAFT FORMERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ALGINATES/RAFT FORMERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL INTERVENTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL INTERVENTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL INTERVENTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DEVICE-BASED THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DEVICE-BASED THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DEVICE-BASED THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY LIQUID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY LIQUID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY LIQUID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY SUSPENSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY SUSPENSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY SUSPENSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MEDICINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY OVER-THE-COUNTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY OVER-THE-COUNTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY OVER-THE-COUNTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PRESCRIPTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PRESCRIPTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PRESCRIPTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG STATUS, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY BRANDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY BRANDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY GENERIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY GENERIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MILD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MILD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MILD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MODERATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MODERATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MODERATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY SEVERE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY SEVERE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY SEVERE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MUCOSAL COATING AGENT, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MEDICINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG STATUS, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MUCOSAL COATING AGENT, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MEDICINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG STATUS, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MUCOSAL COATING AGENT, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MEDICINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG STATUS, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MUCOSAL COATING AGENT, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MEDICINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG STATUS, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MUCOSAL COATING AGENT, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MEDICINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG STATUS, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MUCOSAL COATING AGENT, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MEDICINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG STATUS, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MUCOSAL COATING AGENT, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MEDICINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG STATUS, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MUCOSAL COATING AGENT, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MEDICINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG STATUS, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MUCOSAL COATING AGENT, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MEDICINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG STATUS, 2018-2032 (USD MILLION)
  • TABLE 194. ASEAN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. GCC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 198. GCC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. GCC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 200. GCC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MUCOSAL COATING AGENT, 2018-2032 (USD MILLION)
  • TABLE 201. GCC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 202. GCC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 203. GCC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MEDICINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. GCC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG STATUS, 2018-2032 (USD MILLION)
  • TABLE 205. GCC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 206. GCC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 207. GCC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MUCOSAL COATING AGENT, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MEDICINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG STATUS, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPEAN UNION GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MUCOSAL COATING AGENT, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 224. BRICS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MEDICINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. BRICS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG STATUS, 2018-2032 (USD MILLION)
  • TABLE 227. BRICS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 228. BRICS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 229. BRICS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 230. G7 GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 231. G7 GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. G7 GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 233. G7 GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MUCOSAL COATING AGENT, 2018-2032 (USD MILLION)
  • TABLE 234. G7 GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 235. G7 GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 236. G7 GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MEDICINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. G7 GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG STATUS, 2018-2032 (USD MILLION)
  • TABLE 238. G7 GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 239. G7 GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 240. G7 GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 241. NATO GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 242. NATO GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. NATO GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 244. NATO GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MUCOSAL COATING AGENT, 2018-2032 (USD MILLION)
  • TABLE 245. NATO GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 246. NATO GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 247. NATO GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MEDICINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. NATO GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG STATUS, 2018-2032 (USD MILLION)
  • TABLE 249. NATO GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 250. NATO GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 251. NATO GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 252. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MUCOSAL COATING AGENT, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 258. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MEDICINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG STATUS, 2018-2032 (USD MILLION)
  • TABLE 261. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 262. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 263. UN